Evidence map›Paper›PMID 38139834›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Advantages of Long-Wavelength Photosensitizer

Ekaterina Plotnikova, Elena Nemtsova, Maxim Abakumov, Nikita Suvorov, Andrey Pankratov, Peter Shegai, Andrey Kaprin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ekaterina PlotnikovaMoscow Hertsen Research Institute of Oncology-Branch of the FSBI "National Medical Research Radiology Centre" of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia.ORCID 0000-0001-8711-6919
Elena NemtsovaMoscow Hertsen Research Institute of Oncology-Branch of the FSBI "National Medical Research Radiology Centre" of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia.
Maxim AbakumovDepartment of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia.ORCID 0000-0003-2622-9201
Nikita SuvorovInstitute of Fine Chemical Technologies, MIREA-Russian Technological University, 119571 Moscow, Russia.
Andrey PankratovMoscow Hertsen Research Institute of Oncology-Branch of the FSBI "National Medical Research Radiology Centre" of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia.
Peter ShegaiMoscow Hertsen Research Institute of Oncology-Branch of the FSBI "National Medical Research Radiology Centre" of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia.
Andrey KaprinMoscow Hertsen Research Institute of Oncology-Branch of the FSBI "National Medical Research Radiology Centre" of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia.
Ministry of Health of the Russian Federation · RUMIREA - Russian Technological University · RUPirogov Russian National Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This research presents a novel synthetic photosensitizer for the photodynamic therapy (PDT) of malignant tumors: meso-tetra(3-pyridyl) bacteriochlorin, which absorbs at 747 nm (in the long-wavelength region of the spectrum) and is stable when stored in the dark. H

Indexed as

bacteriochlorinscellphotocytotoxicityphotodynamic therapyphotoinduced antitumor activityphotosensitizertissuetumor

Identifiers

PMID38139834
PMCPMC10747584
OpenAlexW4389566146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.